This study plans to enroll 1248 patients with supratentorial ICH within 24 hours of onset across multiple stroke centers. After randomization, the control group will only receive medical therapy. The experimental group, after randomization, will receive an initial dose of 200 mg of minocycline hydrochloride capsules in addition to medical ttherapy, followed by 100 mg orally every 12 hours for 7 days, resulting in a total of 14 administrations. Both groups will be followed for 180 days to evaluate the efficacy and safety of minocycline in the treatment of ICH.
Age ≥ 18 years, regardless of gender;
Supratentorial ICH confirmed by brain CT scan;
No disability in the community before ICH (premorbid mRS≤1);
Neurological deficits related to the hematoma, with NIHSS score ≥ 6 and single-limb motor item score ≥ 2;
Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs;
Allergy to tetracycline antibiotics;
Use of vitamin A derivatives or steroid therapy within the past 3 months;
Concomitant infection requiring antibiotic treatment at admission;